GILD Logo

Gilead Sciences, Inc. (GILD) 

NASDAQ
Market Cap
$112.43B
Sector
Healthcare
Industry
Drug Manufacturers—General
Rank in Sector
540 of 775
Rank in Industry
10 of 10

Largest Insider Buys in Sector

GILD Stock Price History Chart

GILD Stock Performance

About Gilead Sciences, Inc.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, …

Insider Activity of Gilead Sciences, Inc.

Over the last 12 months, insiders at Gilead Sciences, Inc. have bought $0 and sold $10.53M worth of Gilead Sciences, Inc. stock.

On average, over the past 5 years, insiders at Gilead Sciences, Inc. have bought $0 and sold $6.22M worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 20,000 shares for transaction amount of $2M was made by WOLD OLSEN PER (director) on 2015‑02‑06.

List of Insider Buy and Sell Transactions, Gilead Sciences, Inc.

2024-11-06SaleChief Medical Officer
25,590
0.0021%
$91.50$2.34M+1.96%
2024-11-06SaleChief Commercial Officer
5,000
0.0004%
$91.28$456,400+1.96%
2024-10-01SaleChief Medical Officer
2,000
0.0002%
$83.83$167,660+4.50%
2024-09-12SaleChief Medical Officer
21,246
0.0017%
$84.50$1.8M+4.36%
2024-09-12SaleChief Commercial Officer
29,357
0.0024%
$83.78$2.46M+4.36%
2024-08-28SaleChief Commercial Officer
9,513
0.0008%
$78.03$742,299+7.87%
2024-08-13SaleChief Commercial Officer
5,490
0.0004%
$73.98$406,1500.00%
2024-07-01SaleChief Medical Officer
2,000
0.0002%
$68.63$137,2600.00%
2024-04-01SaleChief Medical Officer
2,000
0.0002%
$72.96$145,920+0.86%
2024-02-29SaleChief Medical Officer
8,230
0.0007%
$72.74$598,624+1.66%
2024-02-28SaleChief Medical Officer
2,000
0.0002%
$73.18$146,360+0.77%
2024-01-16SaleChief Financial Officer
5,000
0.0004%
$85.78$428,900-14.22%
2024-01-09SaleChief Commercial Officer
8,242
0.0007%
$85.23$702,466-14.39%
2023-10-17SaleChief Financial Officer
5,000
0.0004%
$80.00$400,017-6.68%
2023-09-12SaleChief Medical Officer
1,501
0.0001%
$76.99$115,562-2.57%
2023-07-20SaleChief Financial Officer
5,000
0.0004%
$80.00$400,000-5.94%
2023-06-13SaleChief Medical Officer
1,485
0.0001%
$76.90$114,197-2.34%
2023-03-13SaleChief Medical Officer
6,126
0.0005%
$78.99$483,893-0.46%
2023-03-01SaleChief Medical Officer
12,984
0.001%
$79.96$1.04M-0.40%
2022-12-30SaleChief Medical Officer
553
<0.0001%
$85.33$47,187-7.23%

Insider Historical Profitability

12.52%
MARTIN JOHN Cdirector
2877762
0.2309%
$90.211157+15.06%
MILLIGAN JOHN FPresident and CEO
1165924
0.0936%
$90.21153+12.4%
WOLD OLSEN PERdirector
97854
0.0079%
$90.2143+18.87%
HILLS CARLA Adirector
2742
0.0002%
$90.2120<0.0001%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
BlackRock$8.98B9.84122.53M-0.21%-$19.19M0.2
The Vanguard Group$8.4B9.21114.73M+2.6%+$213.17M0.16
Capital World Investors$6.19B6.7884.5M+1.36%+$83.01M1.03
Capital Research Global Investors$4.49B4.9261.25M+2.66%+$116.41M1.02
State Street$4.23B4.6357.7M-3.08%-$134.16M0.17
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.